Current Report Filing (8-k)
30 September 2022 - 06:16AM
Edgar (US Regulatory)
0000012239 false 0000012239 2022-09-23
2022-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 23, 2022
AIKIDO PHARMA INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-05576 |
|
52-0849320 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
|
One Rockefeller Plaza,
11th Floor,
New York,
NY |
|
10020 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone number, including area code:
(703)
993-9325
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13a-4(c)) |
|
Title of each
class |
Trading Symbol(s) |
Name of each exchange on which
registered |
|
Common Stock, $0.0001 par value |
AIKI |
The
Nasdaq Capital Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 1.01. |
Entry Into a Material Definitive Agreement. |
On September 23, 2022, Dominari Financial, Inc. (“Dominari”), a
wholly owned subsidiary of AIkido Pharma, Inc, (the “Company”)
entered into a Lease Agreement (the “Lease”) with Trump Tower
Commercial LLC, a New York limited liability company.
Pursuant to the Lease, Dominari will rent a portion of a floor at
725 Fifth Avenue, New York, New York (the “Premises”). Dominari
plans to use the Premises to run its day-to-day operations.
The initial term of the Lease is seven (7) years commencing on the
date that possession of the Premises is delivered to Dominari.
Pursuant to the Lease, Dominari will pay rent equal to forty-nine
thousand three hundred and sixty-eight dollars per month. Effective
for the sixth and seventh years of the Lease, the rent shall
increase to fifty-one thousand eight hundred and sixty-eight
dollars per month.
The foregoing is a summary of the terms of the Lease, a copy of the
Lease will be filed with the Company’s next Quarterly Report on
Form 10-Q.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Dated:
September 29, 2022 |
AIKIDO
PHARMA INC. |
| |
|
| |
By: |
/s/
Anthony Hayes |
| |
Name: |
Anthony
Hayes |
| |
Title: |
Chief
Executive Officer |
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From May 2023 to Jun 2023
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Jun 2022 to Jun 2023
